22 U.S.C. § 7635 — Report on treatment activities by relevant executive branch agencies

submitted 23 years ago by Pub. L. 108-25 to r/title-22-FOREIGN-RELATIONS-AND-INTERCOURSE · 250 words · no verdicts yet

in plain englishAI-generated · not legal advice

Within 15 months of May 27, 2003, the President had to report to Congress on U.S. agencies' work treating HIV/AIDS abroad. The report had to cover treatment methods, pilot projects, and how treatment connects to preventing HIV's spread.

(a) In general: No later than 15 months after May 27, 2003, the President had to send Congress a report on federal agencies' programs treating people abroad who have HIV or AIDS. (b) Report elements: The report had to include: (1) A description of agencies' work on (A) treating opportunistic infections; (B) using antiretroviral drugs; (C) research into successful treatment methods for the developing world; (D) training local health workers to give antiretrovirals, manage side effects, and monitor patients; (E) keeping HIV/AIDS drugs available long-term and dealing with drug resistance; and (F) law enforcement work to stop counterfeit and black-market HIV/AIDS drugs. (2) Information on existing pilot projects — why each population was chosen, how many people were treated, the cost, how treatment was checked for safety and effectiveness, and plans to expand the projects, including timelines and needed resources. (3) An explanation of how these activities help prevent HIV from spreading.

the actual law source: uscode.house.gov ↗public domain

(a) In general

Not later than 15 months after May 27, 2003, the President shall submit to appropriate congressional committees a report on the programs and activities of the relevant executive branch agencies that are directed to the treatment of individuals in foreign countries infected with HIV or living with AIDS.

(b) Report elements

The report shall include—

(1)

a description of the activities of relevant executive branch agencies with respect to—

(A)

the treatment of opportunistic infections;

(B)

the use of antiretrovirals;

(C)

the status of research into successful treatment protocols for individuals in the developing world;

(D)

technical assistance and training of local health care workers (in countries affected by the pandemic) to administer antiretrovirals, manage side effects, and monitor patients’ viral loads and immune status;

(E)

the status of strategies to promote sustainability of HIV/AIDS pharmaceuticals (including antiretrovirals) and the effects of drug resistance on HIV/AIDS patients; and

(F)

the status of appropriate law enforcement officials working to ensure that HIV/AIDS pharmaceutical treatment is not diminished through illegal counterfeiting and black market sales of such pharmaceuticals;

(2)

information on existing pilot projects, including a discussion of why a given population was selected, the number of people treated, the cost of treatment, the mechanisms established to ensure that treatment is being administered effectively and safely, and plans for scaling up pilot projects (including projected timelines and required resources); and

(3)

an explanation of how those activities relate to efforts to prevent the transmission of the HIV infection.

Source credit: (Pub. L. 108–25, title III, § 305, May 27, 2003, 117 Stat. 739.)

history & why it existsrecord from the source credit

2003Enacted · Pub. L. 108-25 · 117 Stat. 739

A history note hasn’t been published yet. The record shows enactment by Pub. L. 108-25 on 2003-05-27.

all 0 arguments · sorted by: best

no arguments yet — make the first case